Online Program Home
My Program

Abstract Details

Activity Number: 129 - Adaptive Design - 1
Type: Contributed
Date/Time: Monday, July 30, 2018 : 8:30 AM to 10:20 AM
Sponsor: Biopharmaceutical Section
Abstract #330751 Presentation
Title: Formulation of Data Monitoring Committee Recommendations for Adaptive Design Clinical Trials
Author(s): Navneet Hakhu*
Companies: Axio Research
Keywords: Data Monitoring Committee; Clinical Trial; Interim Monitoring; Adaptive Design; Recommendations; Program-wide DMCs

Data Monitoring Committees (DMCs) are charged with monitoring ongoing clinical trial(s) to protect the interests of participating human volunteers and preserve trial integrity through interim reviews of safety and efficacy data. The DMC's assessment of risk-benefit forms the basis of the committee's recommendations to the sponsor to continue, stop, or modify the trial. Pre-specified monitoring guidelines (stopping boundaries) may be incorporated into an adaptive component of a trial's design for efficacy, futility, and/or safety/harm, which can facilitate the DMC's assessment. In this talk, I will focus on adaptive design clinical trials with pre-specified monitoring guidelines and how the DMC's formulation of recommendations based on a risk-benefit assessment are impacted by: 1) types of boundaries pre-specified ('hard' = must recommend stopping if boundary crossed, or 'soft' = consider recommending stopping if boundary crossed); 2) information to be conveyed to the appropriate sponsor representative; and 3) whether the DMC is monitoring a single trial or multiple trials for the same investigational product (program-wide DMCs).

Authors who are presenting talks have a * after their name.

Back to the full JSM 2018 program